Nasal DIMEB Delivery Bypasses Blood-Brain Barrier for Prion Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prion neurodegenerative diseases are ineffective as cyclodextrins, which show potential, struggle to cross the blood-brain barrier, and existing administration methods are invasive and risky.
Innovation Solution
Nasal administration of dimethyl-beta-cyclodextrin (DIMEB) to bypass the blood-brain barrier, utilizing the olfactory and trigeminal nerves for direct access to the central nervous system, with a controlled delivery system to ensure safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cyclodextrins are administered systemically (intraperitoneally or subcutaneously), then they can reach the brain, but they require extremely high doses and cause pulmonary toxicity
Solution Approach 1:
The patent uses the olfactory mucosa and olfactory nerve pathway as an intermediary route to deliver cyclodextrins directly to the brain, bypassing the blood-brain barrier and avoiding systemic circulation. This mediator pathway allows therapeutic delivery without the toxic effects of high-dose systemic administration
Solution Approach 2:
The patent segments the delivery pathway by utilizing the specific anatomical route through the nasal cavity and olfactory nerve, separating brain delivery from systemic circulation. This segmentation allows targeted delivery to the CNS while avoiding pulmonary toxicity associated with systemic administration
2Reliability
If cyclodextrins are administered intracerebroventricularly, then they are highly effective at low doses, but the method is invasive and requires surgical expertise
Solution Approach 1:
The olfactory mucosa and olfactory nerve serve as natural intermediaries that enable non-invasive delivery of cyclodextrins to the brain. This intermediary pathway eliminates the need for surgical intervention while maintaining effective drug delivery to the central nervous system
Solution Approach 2:
Instead of delivering drugs from the inside out (invasive intracerebral injection), the patent inverts the approach by delivering through the nose from the outside in, utilizing the retrograde transport via olfactory nerves to reach the brain without surgery
3Ease of operation
If cyclodextrins are administered nasally, then they can bypass the blood-brain barrier, but existing formulations lack proven efficacy for prion diseases
Solution Approach 1:
The patent modifies the cyclodextrin molecule by adding a lysine residue to create a basic amino group, changing the chemical parameters of the compound. This modification enhances binding to prion proteins and improves efficacy for prion disease treatment while maintaining nasal delivery capability
Solution Approach 2:
The patent creates a composite structure by conjugating cyclodextrin with a basic amino group (lysine), combining the solubilization and inclusion properties of cyclodextrin with the prion-binding capability of basic amino groups, resulting in a compound with enhanced disease-modifying efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DIMEB effectively inhibits prion protein aggregation and accumulation, providing a non-invasive and safe treatment option for prion diseases by maximizing brain penetration and minimizing systemic circulation and inflammation.
Implementation Method 1
Cyclodextrins, with their lipophilic internal cavities and hydrophilic external surfaces, are likely to interact with many molecules to form non-covalent inclusion complexes
Implementation Method 2
Nasal administration of dimethyl-beta-cyclodextrin (DIMEB) to bypass the blood-brain barrier, utilizing the olfactory and trigeminal nerves for direct access to the central nervous system
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3~4B
AI summary
The invention relates to the treatment of a prion neurodegenerative disease by nasal administration of 2,6-di-O-methyl-beta-cyclodextrin (DIMEB).